Investigational Drug Details
| Drug ID: | D316 |
| Drug Name: | S-adenosyl-L-methionine |
| Synonyms: | SAMe; Ademetionine; AdoMet; L-S-Adenosylmethionine; S-Adenosylmethionine; SAM; SAM-e; SAMe |
| Type: | Chemical drug |
| DrugBank ID: | DB00118 |
| DrugBank Description: | Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed) |
| PubChem ID: | 34755 |
| CasNo: | 29908-03-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | O[C@H]1[C@H](n2c3c(nc2)c(N)ncn3)O[C@@H]([C@H]1O)C[S+](CC[C@@H](C(=O)[O-])N)C |
| Structure: |
|
| InChiKey: | MEFKEPWMEQBLKI-AIRLBKTGSA-N |
| Molecular Weight: | 398.445 |
| DrugBank Targets: | Glycine N-methyltransferase cofactor; S-adenosylmethionine decarboxylase proenzyme cofactor; S-adenosylmethionine synthase isoform type-2 cofactor; Cystathionine beta-synthase activator; S-adenosylmethionine synthase isoform type-1 cofactor; Catechol O-me |
| DrugBank MoA: | S-Adenosylmethionine (SAMe) is a natural substance present in the cells of the body. It is a direct metabolite of the essential amino acid L-methionine. SAMe plays a crucial biochemical role in the body by donating a one-carbon methyl group in a process called transmethylation. SAMe, formed from the reaction of L-methionine and adenosine triphosphate catalyzed by the enzyme S-adenosylmethionine synthetase, is the methyl-group donor in the biosynthesis of both DNA and RNA nucleic acids, phospholipids, proteins, epinephrine, melatonin, creatine and other molecules. |
| DrugBank Pharmacology: | S-adenosylmethionine is an intermediate metabolite of methionine. Its involvement in methylation assists in cellular growth and repair, maintains the phospho-bilipid layer in cell membranes. It also helps in the maintenance of the action of several hormones and neurotransmitters that affect mood. Highest concentration are found in the brain and the liver. |
| DrugBank Indication: | S-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being. |
| Targets: | GNMT cofactor |
| Therapeutic Category: | Antiviral |
| Clinical Trial Progress: | Phase 3 on-going (DRKS00005767) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0058 | NCT01754714 | Phase 3 | Completed | Has Results | December 2012 | February 19, 2016 | Details |
| L0548 | DRKS00005767 | Phase 3 | Not Recruiting | No Results Available | 10/05/2017 | 7 February 2022 | Details |
| L0654 | EUCTR2012-000975-18-DE | Not applicable | Not Recruiting | No Results Available | 03/07/2012 | 27 October 2014 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00271 | 35159219 | Cells | S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. | Details |
| A05745 | 33134907 | JHEP Rep | Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. | Details |
| A06726 | 32768187 | Biochem Biophys Res Commun | Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH. | Details |
| A10996 | 31086990 | Toxicol Sci | Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis. | Details |
| A13930 | 29683981 | Eur J Gastroenterol Hepatol | Chronic liver diseases and the potential use of S-adenosyl-L-methionine as a hepatoprotector. | Details |
| A21489 | 25281863 | J Hepatol | Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways. | Details |
| A35544 | 20395294 | J Biol Chem | Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. | Details |
| A47345 | 15368449 | Hepatology | Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. | Details |
| A47355 | 12940921 | Aliment Pharmacol Ther | Review article: Nutritional therapy in alcoholic liver disease. | Details |
| A47465 | 1345200 | Acta Physiol Hung | Pathogenesis and management of alcoholic liver injury. | Details |
| A52711 | 23104821 | Drug Metabol Drug Interact | CYP2E1 potentiates toxicity in obesity and after chronic ethanol treatment. | Details |
| A53178 | 2405596 | Adv Intern Med | Diagnosis and management of liver disease in pregnancy. | Details |